Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
2022 · Nature Medicine · 183 citations
https://doi.org/10.1038/s41591-022-01916-x
N
Nathalie Scholler
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
170
Papers
5.7K
Citations
37
h-index
55
i10-index
Nathalie Scholler is an academic researcher from Atara Biotherapeutics (United States). The author has contributed to research in topics: CAR-T cell therapy research & Immunotherapy and Immune Responses & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 37, co-authored 145 publications.
ORCID: 0000-0003-3743-7102Papers by this author
worksTumor-associated B-cells induce tumor heterogeneity and therapy resistance
2017 · Nature Communications · 139 citations
https://doi.org/10.1038/s41467-017-00452-4
IL-4 drives exhaustion of CD8+ CART cells
2024 · Nature Communications · 29 citations
https://doi.org/10.1038/s41467-024-51978-3
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
2003 · PubMed · 19 citations
Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms
2019 · Scientific Reports · 18 citations
https://doi.org/10.1038/s41598-019-41567-6
Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library
2012 · BMC Biotechnology · 7 citations
https://doi.org/10.1186/1472-6750-12-23
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat